Search

Displaying results 3991 - 4000 of 9886 in total
  1. Drug

    Tebapivat

    go.drugbank.com/drugs/DB19338
    Investigational

    Tebapivat is under investigation in clinical trial NCT05490446 (A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-risk Myelodysplastic Syndromes (LR-MDS)).

    Synonyms: 6-[(6-aminopyridin-2-yl)methyl]-4-methyl-2-[(1H-pyrazol-3-yl)methyl]-4,6-dihydro-5H-[1,3]thiazolo[5',4':4,5]pyrrolo[2,3-d]pyridazin-5-one
  2. Drug

    Yohimbine

    go.drugbank.com/drugs/DB01392
    ApprovedInvestigationalVet approvedWithdrawn

    A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of impotence. It is also alleged to be an aphrodisiac.

    Categories: Dopamine D2 Receptor Antagonists
  3. Drug

    Sparteine

    go.drugbank.com/drugs/DB06727
    ApprovedWithdrawn

    It is a sodium channel blocker, so it falls in the category of class 1a antiarrhythmic agents. … Sparteine is a plant alkaloid derived from _Cytisus scoparius_ and _Lupinus mutabilis_ which may chelate calcium and magnesium.

    Categories: Antiarrhythmics, Class Ia
  4. Drug

    Nesvategrast

    go.drugbank.com/drugs/DB19337
    Investigational

    Nesvategrast is under investigation in clinical trial NCT05409235 (Nesvategrast (OTT166) in Diabetic Retinopathy (DR)).

  5. Drug

    Pumactant

    go.drugbank.com/drugs/DB04955
    Experimental

    Pumactant is a synthetic surfactant used for treating respiratory distress syndrome in neonates. … It is a unique formulation of the naturally occurring phospholipids Dipalmitoylphosphatidycholine (DPPC) and Phosphatidyl Glycerol (PG).

  6. Drug

    Fulzerasib

    go.drugbank.com/drugs/DB21609
    Investigational

    Fulzerasib has a monoisotopic molecular weight of 630.22 Da. … Fulzerasib is a small molecule drug. The usage of the INN stem '-rasib' in the name indicates that Fulzerasib is a Ras protein inhibitor.

  7. Drug

    DR-01

    go.drugbank.com/drugs/DB18258
    Investigational

    DR-01 is a monoclonal antibody directed against human CD94.

  8. Drug

    Bimekizumab

    go.drugbank.com/drugs/DB12917
    ApprovedInvestigational

    Bimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in the EU on August 20, 2021, for the treatment of plaque psoriasis. … [A244455] It has demonstrated superior efficacy as compared to another IL-17 inhibitor, [secukinumab], as well as [ustekinumab] (an IL-12/23 inhibitor) and [adalimumab] (a TNF inhibitor) in the treatment

  9. Drug

    Palbociclib

    go.drugbank.com/drugs/DB09073
    ApprovedInvestigational

    It is a second generation cyclin-dependent kinase inhibitor[A176798] selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. … Palbociclib is a piperazine pyridopyrimidine[A176792] that acts in the cell cycle machinery.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSynonyms: 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one
  10. Drug

    Crizanlizumab

    go.drugbank.com/drugs/DB15271
    ApprovedInvestigational

    [L10097] While crizanlizumab received conditional marketing authorization from the EMA in October 2020, this approval was revoked in August 2023 due to concerns over the efficacy and safety of the drug … [A187904] Though hydroxyurea has been shown to reduce the frequency of vaso-occlusive crises, adherence to this therapy is difficult due to adverse effects and the high variability of response to the drug